Yogamet-GM 2 Tablet PR contains a combination of Glimepiride (2mg) and Metformin (500mg), formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscles. This dual-action mechanism addresses hyperglycemia through complementary pathways, making Yogamet-GM 2 effective in achieving glycemic control in patients inadequately managed by diet and exercise alone. The prolonged-release formulation ensures a steady release of active ingredients, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Yogamet-GM 2 is indicated as monotherapy or in combination with other antidiabetic agents when diet and exercise do not provide adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Use of this medication should be accompanied by lifestyle modifications, including diet and physical activity. Contraindications include severe renal impairment, metabolic acidosis, and known hypersensitivity to components. Caution is advised in patients with hepatic dysfunction or cardiovascular disease.